Clinical Trial Update: A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the immunogenicity, safety and tolerability of the Ebola vaccine regimen Ad26.ZEBOV prime followed by MVA-BN-Filo boost in healthy adul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ad26.ZEBOV
• MVA-BN-Filo

Snippet

Sponsor: Crucell Holland BV | Conditions: Healthy | Phase 3 | Status: COMPLETED